{"id":30709,"date":"2022-06-16T17:37:18","date_gmt":"2022-06-16T23:37:18","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=30709"},"modified":"2022-06-16T17:37:18","modified_gmt":"2022-06-16T23:37:18","slug":"brakke-viewpoint-june-17-2022","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/","title":{"rendered":"Ponto de vista de Brakke 17 de junho de 2022"},"content":{"rendered":"<p>A primeira vacina contra a peste su\u00edna africana (PSA) comercialmente dispon\u00edvel no mundo est\u00e1 sendo testada em campo para seguran\u00e7a e efic\u00e1cia no Vietn\u00e3. Embora este seja um marco importante no controle e preven\u00e7\u00e3o da PSA, devemos estar cientes de que esta \u00e9 uma vacina de v\u00edrus vivo modificado (MLV) e um ensaio diagn\u00f3stico DIVA (diferenciar animais infectados de animais vacinados) que pode distinguir porcos vacinados daqueles infectados com PSA selvagem v\u00edrus ainda n\u00e3o foi desenvolvido.<\/p>\n<p>Para controlar e erradicar efetivamente a PSA, os pesquisadores devem continuar a desenvolver vacinas de subunidades (prote\u00ednas e pept\u00eddeos) e nucleot\u00eddeos (DNA e RNA) que sejam inerentemente mais seguras e compat\u00edveis com DIVA. Os ensaios DIVA s\u00e3o extremamente \u00fateis para o controle de uma doen\u00e7a infecciosa rec\u00e9m-emergida ou de uma doen\u00e7a animal estranha, pois podem permitir a estrat\u00e9gia \u201cvacinar para viver\u201d pela qual os animais vacinados podem ser criados e processados para produ\u00e7\u00e3o e consumo de alimentos e\/ou vendidos no com\u00e9rcio internacional.<\/p>\n<p>Al\u00e9m de tornar as vacinas ASF seguras e eficazes acess\u00edveis e dispon\u00edveis em todo o mundo, tamb\u00e9m devemos priorizar os esfor\u00e7os de P&amp;D para aumentar nossa compreens\u00e3o da sobreviv\u00eancia do v\u00edrus ASFV no ambiente e avaliar desinfetantes viricidas de baixo custo e ecol\u00f3gicos em condi\u00e7\u00f5es de campo. Levou muito tempo para chegar at\u00e9 aqui com uma vacina MLV para ASF e esperamos que as vacinas DIVA sejam testadas em campo em breve.<\/p>\n<p><em>Jishu Shi<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>A primeira vacina comercialmente dispon\u00edvel contra a Peste Su\u00edna Africana (PSA) no mundo est\u00e1 actualmente a ser testada no terreno quanto \u00e0 seguran\u00e7a e efic\u00e1cia no Vietname. Embora este seja um marco importante no controlo e preven\u00e7\u00e3o da PSA, devemos estar cientes de que se trata de uma vacina de v\u00edrus vivo modificado (VML) e de um ensaio de diagn\u00f3stico DIVA (diferenciar animais infectados de animais vacinados) que pode distinguir os porcos vacinados daqueles infectados com PSA de tipo selvagem. v\u00edrus ainda n\u00e3o foi desenvolvido. Para controlar e erradicar eficazmente a PSA, os investigadores devem continuar a desenvolver vacinas de subunidades (prote\u00ednas e p\u00e9ptidos) e de nucle\u00f3tidos (ADN e ARN) que sejam inerentemente mais seguras e compat\u00edveis com DIVA. Os ensaios DIVA s\u00e3o extremamente \u00fateis para o controlo de uma doen\u00e7a infecciosa recentemente emergente ou de uma doen\u00e7a animal estranha, pois podem permitir a estrat\u00e9gia \u201cvacinar para viver\u201d, atrav\u00e9s da qual os animais vacinados podem ser criados e processados para produ\u00e7\u00e3o e consumo de alimentos e\/ou vendidos no com\u00e9rcio internacional. Al\u00e9m de tornar as vacinas seguras e eficazes contra a PSA acess\u00edveis e dispon\u00edveis em todo o mundo, devemos tamb\u00e9m dar prioridade aos esfor\u00e7os de I&amp;D para aumentar a nossa compreens\u00e3o da sobreviv\u00eancia do v\u00edrus PSA no ambiente e avaliar desinfectantes virucidas de baixo custo e ecol\u00f3gicos em condi\u00e7\u00f5es de campo. Demorou muito tempo para chegarmos t\u00e3o longe com uma vacina contendo VVM para a PSA e esperemos que as vacinas DIVA sejam testadas no terreno em breve. Jishu Shi<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-30709","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"The first commercially available African Swine Fever (ASF) vaccine in the world is currently being field tested for safety and efficacy in Vietnam. While this is an important milestone in ASF control and prevention, we should be aware that this is a modified live virus (MLV) vaccine and a DIVA (differentiate infected from vaccinated animals) diagnostic assay that can distinguish vaccinated pigs from those infected with wildtype ASF viruses has yet to be developed. To effectively control and eradicate ASF, researchers should continue to develop subunit (proteins and peptides) and nucleotide (DNA and RNA) vaccines that are inherently safer and DIVA compatible. DIVA assays are extremely useful for the control of a newly emerging infectious disease or a foreign animal disease as they can enable the \u201cvaccinate-to-live\u201d strategy by which vaccinated animals can be raised and processed for food production and consumption and\/or sold into international trade. In addition to making safe and efficacious ASF vaccines affordable and available worldwide, we should also prioritize R&amp;D efforts to increase our understanding of ASFV virus survival in the environment and evaluate low-cost and environmental-friendly virucidal disinfectants under field conditions.\u00a0 It has taken a long time to get this far with an MLV vaccine for ASF and let\u2019s hope DIVA vaccines will be field tested soon. Jishu Shi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-16T23:37:18+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint June 17, 2022\",\"datePublished\":\"2022-06-16T23:37:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\"},\"wordCount\":222,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2022-06-16T23:37:18+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint June 17, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"The first commercially available African Swine Fever (ASF) vaccine in the world is currently being field tested for safety and efficacy in Vietnam. While this is an important milestone in ASF control and prevention, we should be aware that this is a modified live virus (MLV) vaccine and a DIVA (differentiate infected from vaccinated animals) diagnostic assay that can distinguish vaccinated pigs from those infected with wildtype ASF viruses has yet to be developed. To effectively control and eradicate ASF, researchers should continue to develop subunit (proteins and peptides) and nucleotide (DNA and RNA) vaccines that are inherently safer and DIVA compatible. DIVA assays are extremely useful for the control of a newly emerging infectious disease or a foreign animal disease as they can enable the \u201cvaccinate-to-live\u201d strategy by which vaccinated animals can be raised and processed for food production and consumption and\/or sold into international trade. In addition to making safe and efficacious ASF vaccines affordable and available worldwide, we should also prioritize R&amp;D efforts to increase our understanding of ASFV virus survival in the environment and evaluate low-cost and environmental-friendly virucidal disinfectants under field conditions.\u00a0 It has taken a long time to get this far with an MLV vaccine for ASF and let\u2019s hope DIVA vaccines will be field tested soon. Jishu Shi","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/","og_site_name":"Brakke Consulting Website","article_published_time":"2022-06-16T23:37:18+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint June 17, 2022","datePublished":"2022-06-16T23:37:18+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/"},"wordCount":222,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/","url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2022-06-16T23:37:18+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-june-17-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint June 17, 2022"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=30709"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30709\/revisions"}],"predecessor-version":[{"id":30710,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/30709\/revisions\/30710"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=30709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=30709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=30709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}